Yeast-based therapeutic for chronic hepatitis C infection

Details Yeast-based therapeutic for chronic hepatitis C infection Yeast-based therapeutic for chronic hepatitis C infection

2011-08-30

2011-08-30

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S192100, C424S278100, C424S093100, C424S093510, C435S069300, C435S069700, C435S254110, C435S255100

Reexamination Certificate

active

08007816

ABSTRACT:
Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

REFERENCES:
patent: 4775622 (1988-10-01), Hitzeman et al.
patent: 5413914 (1995-05-01), Franzusoff
patent: 5523215 (1996-06-01), Cousens et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5641654 (1997-06-01), Maki et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5830463 (1998-11-01), Duke et al.
patent: 5858378 (1999-01-01), Bostwick
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5919651 (1999-07-01), Hitzeman et al.
patent: 5930463 (1999-07-01), Park
patent: 5961978 (1999-10-01), Gaudernack et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6090546 (2000-07-01), Breivik et al.
patent: 6121020 (2000-09-01), Selby et al.
patent: 6187307 (2001-02-01), Cohen
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6284249 (2001-09-01), Barban
patent: 6326171 (2001-12-01), Selby et al.
patent: 6361969 (2002-03-01), Galeotti
patent: 6521423 (2003-02-01), Houghton et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6562346 (2003-05-01), Paliard et al.
patent: 6613333 (2003-09-01), Leroux-Roels et al.
patent: 6747135 (2004-06-01), Nolan et al.
patent: 6759046 (2004-07-01), Gaudernack et al.
patent: 6861057 (2005-03-01), Gaudernack et al.
patent: 6890737 (2005-05-01), Maertens et al.
patent: 6986892 (2006-01-01), Coit et al.
patent: 6989892 (2006-01-01), White
patent: 7033805 (2006-04-01), Houghton et al.
patent: 7048930 (2006-05-01), Bosman et al.
patent: 7052696 (2006-05-01), Fields et al.
patent: 7078416 (2006-07-01), Gaudernack et al.
patent: 7083787 (2006-08-01), Duke et al.
patent: 7105303 (2006-09-01), Ralston et al.
patent: 7166426 (2007-01-01), Arcangel et al.
patent: 7192927 (2007-03-01), Gaudernack et al.
patent: 7238356 (2007-07-01), Bosman et al.
patent: 7314925 (2008-01-01), Sablon et al.
patent: 7439042 (2008-10-01), Duke et al.
patent: 7465454 (2008-12-01), Franzusoff et al.
patent: 7595060 (2009-09-01), Duke et al.
patent: 2002/0169125 (2002-11-01), Leung et al.
patent: 2003/0035810 (2003-02-01), Caplan
patent: 2003/0064499 (2003-04-01), Houghton et al.
patent: 2004/0009937 (2004-01-01), Chen et al.
patent: 2004/0126395 (2004-07-01), Maertens et al.
patent: 2004/0138204 (2004-07-01), Harrington
patent: 2004/0151735 (2004-08-01), Maertens et al.
patent: 2004/0191270 (2004-09-01), Drane et al.
patent: 2005/0013828 (2005-01-01), George et al.
patent: 2005/0074465 (2005-04-01), Houghton
patent: 2008/0069831 (2008-03-01), Duke et al.
patent: 2008/0069833 (2008-03-01), Franzusoff et al.
patent: 2008/0107671 (2008-05-01), Duke et al.
patent: 2008/0182895 (2008-07-01), Howe et al.
patent: 2009/0098154 (2009-04-01), Franzusoff et al.
patent: 2009/0142366 (2009-06-01), Franzusoff et al.
patent: 2009/0142367 (2009-06-01), Franzusoff et al.
patent: 2010/0150963 (2010-06-01), Duke et al.
patent: 2486400 (1982-01-01), None
patent: WO 92/22571 (1992-12-01), None
patent: WO 93/17110 (1993-09-01), None
patent: WO 02/39951 (2002-05-01), None
patent: WO 2004/005473 (2004-01-01), None
patent: WO 2004/046175 (2004-06-01), None
patent: WO 2004/046176 (2004-06-01), None
patent: WO 2004/058157 (2004-07-01), None
Caumont et al. Expression of functional HIV-1 integrase in the yeastSaccharomyces cerevisiaeleads to the emergence of a lethal phenotype: potential use for inhibitor screening. Current Genetics. 1996. vol. 29, No. 6, p. 503-510.
Cocquerel et al. Charged Residues in the Transmembran Domains of Hepatitis C Virus Glycoproteins Play a Major Role in the Processing, Subcellular Localization, and Assembly of These Envelope Proteins. J. Virology. 2000. vol. 74. No. 8. p. 3623-3633.
Kyono et al. Human eukaryotic initiation factor 4AII associates with hepatitis C virus NS5B protein in vitro. Biochem Biophys Res Commun. Apr. 5, 2002;292(3):659-66.
Isoyama et al. The core protein of hepatitis C virus is imported into the nucleus by transport receptor Kap123p but inhibits Kap121p-dependent nuclear import of yeast AP1-like transcription factor in yeast cells. J Biol Chem. Oct. 18, 2002;277(42):39634-41.
U.S. Appl. No. 12/631,039, filed Dec. 4, 2009, Duke et al.
Duenas-Carrera Santiago: “DNA vaccination against hepatitis C” Current Opinion in Molecular Therapeutics, Current Drugs, London, GB, vol. 6, No. 2,Apr. 1, 2004, pp. 146-150.
Everson Gregory T et al: “Interim results from a randomized, double-blind, placebo-controlled phase 1b study in subjects with chronic HCV after treatment with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins” Hepatology, vol. 44, No. 4, Suppl. 1, Oct. 2006, pp. 697A-698A, XP002554459 & 57th Annual Meeting of the American-Association-For-The-Study-Of-Live R-Diseases; Boston, MA, USA; Oct. 27-31, 2006 ISSN: 0270-9139.
Forns Xavier et al: “The challenge of developing a vaccine against hepatitis C virus.” J. Hepatol., Nov. 2002, vol. 37, No. 5, Nov. 2002, pp. 684-695.
Gallinari P et al: “Multiple enzymatic activities associated with recombinant NS3 protein of Hepatitis C virus” J. Virol., vol. 72, No. 8, Aug. 1, 1998, pp. 6758-6769.
Haller Aurelia et al: “Whole recombinant yeast-based immunotherapy for treatment of chronic hepatitis C infection induces dose-dependent T cell responses and therapeutic effects without vector neutralization” Hepatology, vol. 42, No. 4, Suppl. 1, Oct. 2005, p. 249A, XP002554457 & 56th Annual Meeting of the American-Association-For-The-Study-Of-Live R-Diseases; San Francisco, CA, USA; Nov. 11-15, 2005 ISSN: 0270-9139.
Haller et al: “Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins” Vaccine, Butterworth Scientific. Guildford, GB, vol. 25, No. 8, Jan. 23, 2007, pp. 1452-1463, XP005829882 ISSN: 0264-410X.
Schiff Eugene R et al: “HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and Core: A randomized, double-blind, placebo controlled phase 1B study” Hepatology, vol. 46, No. 4, Suppl. S, Oct. 2007, p. 816A, XP002554458 & 58th Annual Meeting of the American-Association-For-The-Study-Of-Live R-Diseases; Boston, MA, USA; Nov. 2-6, 2007 ISSN: 0270-9139.
Stubbs A C et al: “Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity” Nature Medicine vol. 7, No. 5, May 1, 2001, pp. 625-629.
Supplementary European search report and opinion for European Patent Application No. 05812919.8, mailed Nov. 23, 2009.
Notice of Allowance for U.S. Appl. No. 11/618,833, mailed Oct. 7, 2009.
Notice of Allowance for U.S. Appl. No. 11/618,834, mailed Oct. 8, 2009.
Acosta-Rivero et al., 2002, Biochemical and Biophysical Research Com., 295: 81-84.
Adams et al., 1994, International Reviews of Immunology, 11(2) : 133-141.
Allsopp et al., 1996, European Journal of Immunology, 26(8): 1951-1959.
Bachmann et al., 1994, Curr. Op. Immunol., 6:320-326.
Baker et al., 1988, Cell, 54:335-344.
Bizzini et al., 1990, FEMS Microbiol. Immunol., 64:155-168.
Bourdette et al., 1994, J. Immunol., 152:2510-2519.
Brake et al., 1984, Proc. Natl. Acad. Sci. USA, 81:4642-4646.
Brossier et al., 1999, Infection and Immunity, 67(2): 964-967.
Brown, D., 1995, The Washington Post, “Gene Therapy ‘Oversold’ by Researchers, Journalists”.
Chien et al., 1992, Proc. Natl. Acad Sci. USA., 89:10011-100

Affiliated with

Also associated with

Rating

Yeast-based therapeutic for chronic hepatitis C infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Yeast-based therapeutic for chronic hepatitis C infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Yeast-based therapeutic for chronic hepatitis C infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2783202